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Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many
carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focussed on the role of MK in
pancreatic carcinoma. This study sought to evaluate the clinical significance of MK expression in pancreatic head carcinoma, including
the relationship between immunohistochemical expression and clinicopathologic factors such as prognosis. Immunohistochemical
expression of MK and CD34 was evaluated in pancreatic head carcinoma specimens from 75 patients who underwent surgical
resection. Midkine was expressed in 53.3% of patients. Midkine expression was significantly correlated with venous invasion,
microvessel density, and liver metastasis (P¼0.0063, 0.0025, and 0.0153, respectively). The 5-year survival rate was significantly lower
for patients positive for MK vs patients negative for MK (P¼0.0073). Multivariate analysis revealed that MK expression was an
independent prognostic factor (P¼0.0033). This is the first report of an association between MK expression and pancreatic head
carcinoma. Midkine may play an important role in the progression of pancreatic head carcinoma, and evaluation of MK expression is
useful for predicting malignant properties of pancreatic head carcinoma.
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Patients with adenocarcinoma of the pancreas have worse survival
than patients with any other gastrointestinal malignancy (Silverberg
and Lubera, 1988). The poor prognosis is principally due to
difficulty in diagnosing pancreatic adenocarcinoma at a localised
resectable stage and the propensity towards early tumour
metastasis to regional lymph nodes and the liver. An important
prognostic factor for pancreatic head carcinoma is the presence or
absence of lymphatic and venous invasion. Without the ability to
recruit new vessels, most tumours’ growth is limited. Tumour
angiogenesis is significantly correlated with tumour progression,
invasion, and metastasis and recognised as an important
contributor to poor prognosis (Weidner et al, 1991).
Midkine (MK) is a secreted heparin-binding growth factor with
a molecular weight of 13kDa. It is a product of a retinoic acid-
responsive gene. Midkine and pleiotrophin (PTN) compose the
heparin-binding growth-associated molecule family, which is
distinct from other heparin-binding growth factor families
(Kadomatsu et al, 1988; Tomomura et al, 1990). Midkine and
PTN also lack similarity to other growth factors or cytokines
(Salama et al, 2006). Midkine has the apparent ability to promote
vascularisation and fibroblast growth, suppress apoptosis, and
induce cell migration, and is thought to be involved in
carcinogenesis and tumour progression (Choudhuri et al, 1997;
Kadomatsu and Muramatsu, 2004). All of these studies suggest that
MK plays an important role in carcinogenesis and the development
and metastasis of tumours, and that it could serve as a novel
tumour marker.
As MK is a secretory protein, its level in the blood can be
monitored. In 87% of human adult carcinomas, serum MK is
elevated; the level decreases after tumour removal (Ikematsu et al,
2000). In oesophageal carcinoma, urinary MK is elevated
(Ikematsu et al, 2003), and high level of serum MK is associated
with tumour progression (Obata et al, 2005), tumour size, rate of
positivity for MK, MK immunoreactivity, and poor survival
(Shimada et al, 2003).
MK expression is restricted to some tissues in normal adults.
For example, expression of MK is high in the small intestine,
moderate in the thyroid, and weak in the lung, colon, stomach,
kidney, and spleen. However, none of MK expression is seen in
normal liver. In the last few years, MK was found to be
overexpressed in various human malignant tumours. Northern
blot experiments revealed MK mRNA expression in gastric cancers
(Aridome et al, 1995, 1998), colorectal cancers (Aridome et al,
1995, 1998; Ye et al, 1999), urinary bladder cancer (O’Brien et al,
1996), neuroblastoma (Nakagawara et al, 1995), Wilm’s tumour
(Tsutsui et al, 1993), and astrocytoma (Mishima et al, 1997).
Interestingly, MK mRNA was reported to be extensively expressed
in the early stage of colon cancer carcinogenesis (Ye et al, 1999).
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significantly more prominent in well-differentiated and moderately
differentiated adenocarcinoma than in poorly differentiated
adenocarcinoma (Aridome et al, 1995). Furthermore, overexpres-
sion of MK mRNA is positively correlated with advanced tumours
and poor prognosis, especially in the case of patients with
neuroblastoma and bladder carcinoma (Nakagawara et al, 1995;
O’Brien et al, 1996). Immunohistochemical studies revealed MK
protein expression in other carcinomas, including oral carcinoma
(Ruan et al, 2007), oesophageal carcinoma (Ren and Zhang, 2006),
gastrointestinal stromal tumours (Kaifi et al, 2007), liver
carcinoma (Kato et al, 2000b), lung carcinoma (Sakitani et al,
1999), thyroid carcinoma (Kato et al, 2000a), and prostate
carcinoma (Konishi et al, 1999).
As mentioned above, MK is expressed in a variety of human
malignant tumours, but to our knowledge no study has been
focussed on correlation between MK expression and pancreatic
head carcinoma, one of the most aggressive gastrointestinal
carcinomas. The purpose of this study was (i) to examine the
expression of MK in 75 cases of pancreatic head carcinoma by
immunohistochemical methods, (ii) to explore possible correlation
between MK expression and clinicopathologic variables, and (iii)
to determine the prognostic value of MK expression.
MATERIALS AND METHODS
In accordance with the institutional guidelines of our hospital,
tissue specimens were collected after delivery of informed consent
(Kurahara et al, 2004).
Patients for histological and biochemical analyses
Formalin-fixed, paraffin-embedded blocks were obtained from 75
patients (50 male and 25 female patients) with invasive ductal
adenocarcinoma of the pancreatic head carcinoma, who had
received surgical treatment at Kagoshima University Hospital. All
of the patients underwent macroscopically curative resection by
pancreaticoduodenectomy (PD) with lymph node dissection.
Patients had not received any preoperative chemotherapy or
radiotherapy. Patient age ranged from 42 to 80 years (median
66.2 years). The number of patients with pT1, pT2, pT3, and pT4
tumours was 3 (4.0%), 5 (6.7%), 59 (78.7%), and 8 (10.7%),
respectively.
All of the resected primary tumours and lymph nodes were
histologically examined by haematoxylin and eosin staining using
the tumour-node-metastasis classification system (Sobin, 2003).
Histologically, all of the tumours were invasive ductal adenocarci-
nomas (29 well differentiated, 43 moderately differentiated, and 3
poorly differentiated). Lymphatic invasion was found in 66
tumours (88.0%) and venous invasion in 56 tumours (74.7%).
Lymph node metastasis was found in 47 tumours (62.7%).
After discharge, all patients were followed up every 3 months
with radiography, ultrasonography, and computed tomography.
Usually, most recurrent liver disease was detected by computed
tomography. New lesions detected by imaging were considered
indicative of relapse. The median follow-up period was 20 months
(ranging from 3 to 168 months). During these periods, 28 (37.3%)
patients experienced recurrence of liver disease.
For Western blot analysis, primary pancreatic tumours and non-
cancerous tissues were obtained by PD surgeries from the same
patient. Namely, non-cancerous tissue was dissected from a region
approximately 3cm apart from the cancerous region.
Cell culture
Four pancreatic carcinoma cell lines (PANC-1, MIA PaCa-2,
Capan-1, and AsPC-1) were used. They were all provided by the
American Type Culture Collection (Manassas, VA, USA). PANC-1,
MIA PaCa-2, Capan-1, and AsPC-1 were derived from pancreatic
tubular adenocarcinoma, pancreatic carcinoma, pancreatic adeno-
carcinoma after liver metastasis, and ascites of pancreatic
adenocarcinoma, respectively. These cells were cultured in
Dulbecco’s modified Eagle’s medium (Sigma-Aldrich Co. Ltd, St
Louis, MO, USA) containing 10% fetal bovine serum (Sigma-
Aldrich Co. Ltd) and 100Uml
 1 penicillin and streptomycin in a
atmosphere of 5% CO2 in air.
Immunohistochemical staining
Primary lesions were fixed in 10% formaldehyde, routinely
embedded in paraffin, and cut into 3-mm-thick sections. Sections
were deparaffinised in xylene, rehydrated in graded series of
ethanol, and incubated in 3.0% hydrogen peroxide (H2O2)i n
methanol for 10min to block the endogenous peroxidases. The
slides were autoclaved at 1201C for 10min in 10mM sodium citrate
(pH 6.0) and cooled to room temperature. To block nonspecific
reactions, sections were first incubated in normal rabbit serum
(200-fold diluted; for staining by MK antibody) or normal horse
serum (200-fold diluted; for staining by CD34 antibody) for 30min
at room temperature. They were then incubated overnight at 41C
with anti-MK antibody (human MK goat polyclonal antibody;
Santa Cruz Laboratory, Santa Cruz, CA, USA) diluted 1:200 in
phosphate-buffered saline (PBS) and anti-CD34 antibody (human
CD34 mouse polyclonal antibody; Dako Corporation, Carpinteria,
CA, USA) diluted 1:100 in PBS. The reactions were developed
using the avidin–biotin immunoperoxidase technique (ABC
method) (Hsu et al, 1981). Immunoreactivity was visualised using
the Vectastain Elite ABC kit and a 3,30-diaminobenzidine solution
(Vector Laboratories Inc., Burlingame, CA, USA). Sections were
then lightly counterstained with haematoxylin. For the positive
control, sections known to be positive for MK were stained under
the same conditions. For the negative control, sections were
processed as mentioned above, except that the primary antibody
was replaced by normal goat serum (200-fold diluted). Anti-MK
immunoreactivity was confined primarily to the cytoplasm. All
immunostained slides were evaluated by two independent
observers (SM and ST). Ten fields were randomly selected, and
expression in 1000 tumour cells (100 cells per field) was evaluated
with high-power ( 200) microscopy. First, we classified the
specimens stained by anti-MK antibody with a visual grading
system employed for immunohistochemical evaluation (Moon
et al, 2003). Samples were considered negative if less than 10% of
the cells are stained for MK; weak was defined as 10–25% of the
tumour staining positive; moderate as 25–50% staining, and
strong as more than 50% of the tumour staining positive. More
than 10% positive staining was defined as positive expression.
Microvessel counting
We used in this study anti-CD34 antibody for counting micro-
vessels, because many articles published had employed CD34
immunostaining for analysing microvessel densities (MVD).
Vessels in the five most highly vascularised areas (0.785mm
2 per
field) visualised by CD34 immunostaining were counted under a
light microscope (with  200 power ( 20 objective and  10
ocular)). The MVD was determined using a method previously
described (Weidner et al, 1991). The tumour MVD was calculated
as the mean value for five fields. Tumours with MVDX40 or o40
were classified as having high-grade and low-grade vascularity,
respectively (Figure 3).
Western blotting
Whole-cell lysates were prepared according to the Santa Cruz
protocol. Glysates (12mg) were subjected to immunoblot analysis
using a 15% SDS–polyacrylamide gel and electrotransferred onto
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The filters were incubated with MK antibody (diluted to 1:200
in PBS) followed by peroxidase-conjugated anti-goat IgG anti-
body (diluted to 1:2000 in PBS; Santa Cruz Laboratory) as a
secondary reaction. As an internal control for the amount of
protein loaded, a portion of filters was reacted with anti-b-actin
antibody (diluted to 1:200 in PBS; Santa Cruz Laboratory). After
incubation, they were then reacted with peroxidase-conjugated
anti-goat IgG antibody, as mentioned above. The immunocomplex
was visualised using the ECL Western blot detection system
(Pierce, Rockford, IL, USA). At least three independent experi-
ments were performed.
Statistical analyses
Statistical analysis of group differences was performed using the w
2
test. The Kaplan–Meier method was used to analyse survival after
surgical treatment of patients, and the log-rank test was used to
estimate differences in survival. Prognostic factors were examined
using univariate and multivariate analyses (Cox proportional
hazards regression model). Po0.05 was considered statistically
significant. All statistical analyses were performed using StatView
statistical software version 5.0 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Expression of MK in pancreatic head carcinoma
In 40 of 75 patients (53.3%), positive expression of MK was
observed in the cytoplasm of carcinoma cells (Figure 1B). Notably,
the intensity of MK expression was stronger in areas abundant in
vessels and in the invading border of tumours. However, negative
expression of MK was also seen in some (46.7%, 35 out of 75) of
pancreatic head carcinomas examined (Figure 1C). No immuno-
reactivity or only a slight staining for MK was noted in normal
pancreatic ductal epithelium, which was approximately 3cm apart
from the cancerous region (Figure 1A).
Western blot analysis of MK expression
Western blot analysis demonstrated that MK protein was strongly
expressed in the primary pancreatic carcinomas obtained from two
independent patients. In contrast, in the non-cancerous pancreatic
tissues of the same patients only a little amount of MK protein was
synthesised (Figure 2A). Strong expression of MK protein was also
seen in all four pancreatic carcinoma cell lines (PANC-1, MIA
PaCa-2, Capan-1, and AsPC-1) tested (Figure 2B).
Correlation between MK expression and clinicopathologic
factors
MK expression was significantly associated with the clinico-
pathologic parameters, including venous invasion, liver metastasis,
and MVD grade. In the group with MK-positive tumours, there was
a significantly higher incidence of venous invasion (P¼0.0063),
liver metastasis (P¼0.0153), and MVD grade (P¼0.0021)
(Table 1). However, there was no significant association between
expression of MK and age, gender, histologic type, tumour depth,
cancer stage, lymphatic invasion, or lymph node metastasis
(Table 1).
Relationship between MVD and MK expression
Microvessels are heterogeneously distributed within tumours, and
the MVD is generally greatest at the invading border of tumours.
When MVD was evaluated by staining specimens with CD34
antibody, the number of CD34-positive blood endothelial cells
varied among tumour specimens. In Figure 3A, a tumour with
high-grade MVD is shown as a typical sample. On the other hand,
a tumour with low-grade MVD is shown in Figure 3B. The median
MVD was 41.50711.21 (ranging from 14.1 to 65.3 per field).
Notably, the MVD was significantly (P¼0.0025) higher in the
MK-positive tumours (mean7s.d.¼45.72710.77) than in the
MK-negative tumours (36.69711.91; Figure 4).
A
B
C
Figure 1 Immunohistochemical staining for MK in invasive ductal
adenocarcinoma of the pancreas head. (A) Normal pancreatic ductal
epithelium dissected approximately 3cm apart from the cancerous region
( 200). Note that almost all cells are unstained or stained very slightly by
the antibody. (B) Carcinoma cells positively stained by MK antibody
( 400). Note cytoplasmic staining for MK. (C) Carcinoma cells stained
negatively by MK antibody ( 400).
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The 5-year survival rate of patients with tumours positive for MK
expression was 0.0%, whereas the rate for patients with tumours
negative for MK expression was 19.3%. There was a significant
difference in the 5-year survival rate between patients with tumours
positive and negative for MK expression (P¼0.0073; Figure 5).
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Figure 2 Western blotting for MK protein. (A) Pancreatic primary tumours (PT) and non-cancerous regions (N) dissected approximately 3cm apart from
the cancerous region. Cases 1 and 2 are from each independent patient. (B) Pancreatic carcinoma cell lines. Note the presence of a 13-kDa band
corresponding to MK protein in primary tumours and cultured cells. The presence of a 43-kDa band corresponding to b-actin protein in each sample
indicates that samples are equally loaded.
Table 1 Correlation between MK expression and clinicopathologic
factors in pancreatic head carcinoma
MK expression
Total
n¼75
Positive
n¼40
(53.3%)
Negative
n¼35
(46.7%) P-values
Age (years)
Mean7s.d. 67.478.9 64.979.9 0.2648
Gender
Male 50 (66.7) 23 (57.5) 27 (77.1) 0.0718
Female 25 (33.3) 17 (42.5) 8 (22.9)
Histology
Well 29 (38.7) 14 (35.0) 15 (42.9) 0.2318
Moderately 43 (57.3) 23 (57.5) 20 (57.1)
Poor 3 (4.0) 3 (7.5) 0 (0.0)
pT
pT1 3 (4.0) 1 (2.5) 2 (5.7) 0.3699
pT2 5 (6.7) 1 (2.5) 4 (11.4)
pT3 59 (78.7) 33 (82.5) 26 (74.3)
pT4 8 (10.7) 5 (12.5) 3 (8.6)
pN
Negative 28 (37.3) 14 (35.0) 14 (40.0) 0.6552
Positive 47 (62.7) 26 (65.0) 21 (60.0)
Liver metastasis
Negative 47 (62.7) 20 (50.0) 27 (77.1) 0.0153
Positive 28 (37.3) 20 (50.0) 8 (22.9)
pStage
I 6 (8.0) 1 (2.5) 5 (14.3) 0.3651
IIA 21 (28.0) 13 (32.5) 8 (22.9)
IIB 38 (50.7) 20 (50.0) 18 (51.4)
III 6 (8.0) 4 (10.0) 2 (5.7)
IV 4 (5.3) 2 (5.0) 2 (5.7)
Lymphatic invasion
Negative 9 (12.0) 4 (10.0) 5 (14.3) 0.5688
Positive 66 (88.0) 36 (90.0) 30 (85.7)
Venous invasion
Negative 19 (25.3) 5 (12.5) 14 (40.0) 0.0063
Positive 56 (74.7) 35 (87.5) 21 (60.0)
Microvessel density
Low grade 33 (44.0) 11 (27.5) 22 (62.9) 0.0021
High grade 42 (56.0) 29 (72.5) 13 (37.1)
MK¼midkine; s.d.¼standard deviation.
B
A
Figure 3 Immunohistochemical staining for CD34 protein in invasive
ductal adenocarcinoma of the pancreas head. (A) A microphotograph of
pancreatic head carcinoma stained by CD34 antibody and judged as high-
grade MVDX40 ( 200). (B) A microphotograph of pancreatic head
carcinoma stained by CD34 antibody and judged as low-grade MVDo40
( 200).
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Tables 2 and 3 show the results of univariate and multivariate
analyses of factors related to patient prognosis. Univariate analysis
demonstrated that the factors including lymphatic invasion, lymph
node metastasis, tumour depth, cancer stage, and MK expression
were significantly (Po0.05) related to postoperative survival.
Multivariate regression demonstrated that lymph node metastasis
and MK expression were independent prognostic factors, while
lymphatic invasion and tumour depth were not.
DISCUSSION
Many studies have shown that growth factors not only promote
tissue proliferation, but also induce malignant transformation. In
another word, they involve in the development of neoplasm. In
fact, various growth factors are reported to be overexpressed in
many human tumours. Like other growth factors, MK is known to
promote cell survival (Qi et al, 2000), cell growth (Takei et al, 2001,
2005), and cell migration (Sato et al, 2001). These biological
activities support the hypothesis that MK may involve in
oncogenesis and tumour progression.
Although the biological role of MK in tumour growth and
progression is not fully understood, MK is thought to be a novel
molecular mediator of tumour angiogenesis (Choudhuri et al,
1997; Muramatsu, 2002). This angiogenic role of MK in
tumourigenesis evokes us to suppose that MK expression is also
involved in growth and progression of a tumour (Kadomatsu and
Muramatsu, 2004). To explore the possible correlation between
MK expression and tumour progression, we examined MK
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Figure 4 Microvessel density (MVD) evaluated by CD34 staining and
subsequent observation (0.785mm
2 per field) under a microscope with
 200 power. The MVD (mean7s.d.¼45.72710.77) in MK-positive
tumours was significantly higher than that (36.69711.91) in MK-negative
tumours (P¼0.0025).
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Figure 5 Comparison of survival curves (depicted according to the
Kaplan–Meier method) of patients with pancreatic head carcinomas in
relation to MK expression. The 5-year survival rate was 0.0% for patients
with MK-positive tumours and 19.3% for patients with MK-negative
tumours, which is significantly different (P¼0.0073).
Table 2 Univariate analysis of prognostic factors in pancreatic head
carcinoma
Variables n 5-year survival rate (%) P-values
Age (years)
Over 65 45 10.0 0.3578
Under 64 30 8.9
Gender
Male 50 10.0 0.8857
Female 25 0.0
pT
pT1, 2 8 37.5 0.0470
pT3, 4 67 5.5
pN
Negative 28 20.0 0.0036
Positive 47 2.8
Liver metastasis
Negative 47 13.1 0.1522
Positive 28 3.6
pStage
I, II 65 11.0 0.0136
III, IV 10 0.0
Lymphatic invasion
Negative 9 33.3 0.0297
Positive 66 6.4
Venous invasion
Negative 19 15.8 0.3625
Positive 56 6.7
Microvessel density
Low grade 33 10.6 0.1822
High grade 42 9.5
Midkine expression
Negative 35 19.3 0.0073
Positive 40 0.0
Table 3 Multivariate analyses of prognostic factors in pancreatic head
carcinoma
Independent
factors
Univariate
P-values
Multivariate
P-values
Hazard
ratio
95%
confidence
interval
pT
pT1, 2/pT3, 4 0.0470 0.7197 1.198 0.446–3.220
pN
Negative/positive 0.0036 0.0235 2.003 1.098–3.653
Lymphatic invasion
Negative/positive 0.0297 0.4287 1.458 0.573–3.562
Midkine expression
Negative/positive 0.0073 0.0033 2.143 1.290–3.711
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Western blot experiments revealed that MK was in fact strongly
expressed in four pancreatic carcinoma cell lines (PANC-1, MIA
PaCa-2, Capan-1, and AsPC-1) tested. Midkine expression was also
seen in surgically resected pancreatic specimens. However, normal
pancreatic tissue expressed only a slight amount of MK
(Figure 2A). These findings suggest a possible involvement of
MK in pathogenesis and progression of pancreatic head carcinoma,
as previously suggested for other carcinomas (Aridome et al, 1995;
O’Brien et al,1 9 9 6 ;M o o net al,2 0 0 3 ) .
Using 75 pancreatic head carcinomas, we investigated immu-
nohistochemically whether MK expression was associated with
clinicopathologic factors including prognosis. Midkine expression
was observed in 53.3% of tumours. This rate was consistent with
previous immunohistochemical data obtained from other carci-
nomas, where MK expression had been detected in 32.0–86.3% of
tumours (Konishi et al, 1999; Kato et al, 2000a,b; Ren and Zhang,
2006; Kaifi et al, 2007; Ruan et al, 2007). In this study, MK
expression was found to be significantly associated with venous
invasion, MVD, and liver metastasis. These features appear to be
slightly different from those of other carcinomas. For example, in
oral squamous cell carcinoma, the expression of MK was
significantly correlated with tumour size, clinical stage, MVD,
and vascular endothelial growth factor (VEGF) expression (Ruan
et al, 2007). In oesophageal carcinoma, MK is more intensely
expressed in well-differentiated tumours than in poorly differ-
entiated tumours (Ren and Zhang, 2006). In hepatocellular
carcinoma, no significant differences in MK expression were
found among tumours with different histologic types (Kato et al,
2000b).
High-grade MVD was more often found in MK-positive
tumours, reflecting a possible effect of MK on tumour vascularity
in pancreatic head carcinoma. Consistent with these results,
transfection of the breast carcinoma line MCF-7 with MK
accelerates tumour growth and increases tumour vascularity after
implantation of MK-overexpressing MCF-7 cells into nude mice
(Choudhuri et al, 1997). Another angiogenic factors including
VEGF, basic fibroblast growth factor, and platelet-derived
endothelial cell growth factor appear to be of interest to test
whether they are correlated with MK-positive tumours, although
we have not yet tested these possibilities.
In this study, univariate analysis identified lymphatic invasion,
lymph node metastasis, tumour depth, cancer stage, and MK
expression as prognostic factors. In addition, multivariate analysis
revealed that lymph node metastasis and MK expression were
determined as independent prognostic factors. It was recently
demonstrated that the expression of MK is associated with poor
survival in oral squamous cell carcinoma (Ruan et al, 2007). In
gastrointestinal stromal tumours, MK overexpression is an
independent prognostic factor associated with poor prognosis
(Kaifi et al, 2007). In oesophageal carcinoma, high level of serum
MK is associated with tumour size, positivity rate, MK immuno-
reactivity, and poor survival and defined as an independent
prognostic factor (Shimada et al, 2003).
In conclusion, MK expression in pancreatic head carcinoma was
associated with venous invasion, liver metastasis, MVD, and
prognosis, and defined as an independent prognostic factor. This
is the first report of an association between MK expression and
pancreatic head carcinoma. In this context, MK may be useful as a
new diagnostic and prognostic biomarker in predicting malignant
properties of pancreatic head carcinoma. Furthermore, suppres-
sion of MK gene expression using a recently developed RNAi
technology during pathogenesis and progression of pancreatic
head carcinoma may be an interesting trial for possible inhibition
of this disease.
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